Welcome to LookChem.com Sign In|Join Free

CAS

  • or

14805-29-9

Post Buying Request

14805-29-9 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

14805-29-9 Usage

Uses

Different sources of media describe the Uses of 14805-29-9 differently. You can refer to the following data:
1. (3AR,4S,7R,7AS) 4,7-methylene-1H-isoindole-1,3(2H)-dione can be used as an intermediate for organic synthesis and pharmaceutical research and development, suitable for laboratory organic synthesis It can be used as the raw material for the synthetic raw material medicine lurasidone in the synthesis process of chemical medicine.
2. exo-2,3-Norbornanedicarboximide is a Lurasidone (L474920) intermediate.

Check Digit Verification of cas no

The CAS Registry Mumber 14805-29-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,4,8,0 and 5 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 14805-29:
(7*1)+(6*4)+(5*8)+(4*0)+(3*5)+(2*2)+(1*9)=99
99 % 10 = 9
So 14805-29-9 is a valid CAS Registry Number.

14805-29-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name (3aR,4S,7R,7aS)-Hexahydro-1H-4,7-methanoisoindole-1,3(2H)-dione

1.2 Other means of identification

Product number -
Other names (3aR,4S,7R,7aS)-rel-hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:14805-29-9 SDS

14805-29-9Synthetic route

(1R,2S,6R,7S)-4-azatricyclo[5.2.1.0(2,6)]dec-8-ene-3,5-dione
6265-30-1

(1R,2S,6R,7S)-4-azatricyclo[5.2.1.0(2,6)]dec-8-ene-3,5-dione

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione
14805-29-9

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione

Conditions
ConditionsYield
With palladium 10% on activated carbon; hydrogen In methanol Autoclave; Industrial scale;91.4%
exo-bicyclo[2.2.1]heptane-2,3-dicarboxylic anhydride
14166-28-0

exo-bicyclo[2.2.1]heptane-2,3-dicarboxylic anhydride

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione
14805-29-9

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione

Conditions
ConditionsYield
With ammonium hydroxide In tetrahydrofuran at 190℃; for 2h;80.5%
Multi-step reaction with 2 steps
1: triethylamine / toluene / Reflux
2: pyridine / 0 - 20 °C
View Scheme
Stage #1: exo-bicyclo[2.2.1]heptane-2,3-dicarboxylic anhydride In tetrahydrofuran at 25 - 35℃; for 0.166667h;
Stage #2: With ammonia In tetrahydrofuran; water at 0 - 35℃;
(1R,2R,6S,7S)-4-oxa-tricyclo[5.2.1.02,6]dec-8-ene-3,5-dione
2746-19-2

(1R,2R,6S,7S)-4-oxa-tricyclo[5.2.1.02,6]dec-8-ene-3,5-dione

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione
14805-29-9

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 95.9 percent / H2 / 10percent Pd/C / H2O; tetrahydrofuran / 1.5 h / Ambient temperature
2: 80.5 percent / 7percent aq. NH3 / tetrahydrofuran / 2 h / 190 °C
View Scheme
Multi-step reaction with 2 steps
1: 95.9 percent / H2 / 10percent Pd-C/ 50percent H2O / tetrahydrofuran / 1.5 h / Ambient temperature
2: 80.5 percent / 7percent aq. NH3 / tetrahydrofuran / 2 h / 190 °C
View Scheme
Multi-step reaction with 2 steps
1.1: palladium on activated charcoal; hydrogen / 25 - 35 °C / 3750.38 Torr / Inert atmosphere; Autoclave
2.1: tetrahydrofuran / 0.17 h / 25 - 35 °C
2.2: 0 - 35 °C
View Scheme
(3aR,4S,7R,7aS)-2-(((1R,2R)-2-(hydroxymethyl)cyclohexyl)methy)hexahydro-1H-4,7-methanoisoindole-1,3(2H)-dione

(3aR,4S,7R,7aS)-2-(((1R,2R)-2-(hydroxymethyl)cyclohexyl)methy)hexahydro-1H-4,7-methanoisoindole-1,3(2H)-dione

methanesulfonyl chloride
124-63-0

methanesulfonyl chloride

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione
14805-29-9

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione

Conditions
ConditionsYield
Stage #1: (3aR,4S,7R,7aS)-2-(((1R,2R)-2-(hydroxymethyl)cyclohexyl)methy)hexahydro-1H-4,7-methanoisoindole-1,3(2H)-dione; methanesulfonyl chloride With pyridine at 0 - 20℃;
Stage #2: With hydrogenchloride In water
cyclopenta-1,3-diene
542-92-7

cyclopenta-1,3-diene

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione
14805-29-9

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1.1: 1 h / 200 °C
2.1: palladium on activated charcoal; hydrogen / 25 - 35 °C / 3750.38 Torr / Inert atmosphere; Autoclave
3.1: tetrahydrofuran / 0.17 h / 25 - 35 °C
3.2: 0 - 35 °C
View Scheme
3,6-endomethylene-1,2,3,6-tetrahydrophthalic anhydride
129-64-6

3,6-endomethylene-1,2,3,6-tetrahydrophthalic anhydride

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione
14805-29-9

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: ammonium acetate / 135 °C / Industrial scale
2: hydrogen; palladium 10% on activated carbon / methanol / Autoclave; Industrial scale
View Scheme
1,5-dibromo-pentane
111-24-0

1,5-dibromo-pentane

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione
14805-29-9

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione

N-(4-Bromopentyl)bicyclo<2.2.1>heptane-2,3-di-exo-carboximide
138274-10-9

N-(4-Bromopentyl)bicyclo<2.2.1>heptane-2,3-di-exo-carboximide

Conditions
ConditionsYield
With potassium carbonate In acetone Heating;100%
(1R,2R)-(-)-trans-cyclohexane-1,2-diylbis(methylene)dimethanesulfonate
186204-35-3

(1R,2R)-(-)-trans-cyclohexane-1,2-diylbis(methylene)dimethanesulfonate

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione
14805-29-9

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione

((1R,2R)-2-(((3aR,4S,7R,7aS)-1,3-dioxohexahydro-1H-4,7-methanoisoindol-2(3H)-yl)methyl)cyclohexyl)methylmethanesulfonate

((1R,2R)-2-(((3aR,4S,7R,7aS)-1,3-dioxohexahydro-1H-4,7-methanoisoindol-2(3H)-yl)methyl)cyclohexyl)methylmethanesulfonate

Conditions
ConditionsYield
With potassium carbonate In isopropyl alcohol for 4h;99%
(3aR,7aR)-4’-(benzo[d]isothiazol-3-yl)octahydrospiro[isoindole-2,1’-piperazin]-2-ium methanesulfonate
186204-37-5

(3aR,7aR)-4’-(benzo[d]isothiazol-3-yl)octahydrospiro[isoindole-2,1’-piperazin]-2-ium methanesulfonate

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione
14805-29-9

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione

(3aR,4S,7R,7aS)-2-[((1R,2R)-2-{[4-(l1,2-benzisothiazol-3-yl)piperazin-1-yl]methyl}cyclohexyl)methyl]hexahydro-1H-4,7-methanisoindol-1,3-dione hydrochloride
367514-88-3

(3aR,4S,7R,7aS)-2-[((1R,2R)-2-{[4-(l1,2-benzisothiazol-3-yl)piperazin-1-yl]methyl}cyclohexyl)methyl]hexahydro-1H-4,7-methanisoindol-1,3-dione hydrochloride

Conditions
ConditionsYield
Stage #1: (3aR,7aR)-4’-(benzo[d]isothiazol-3-yl)octahydrospiro[isoindole-2,1’-piperazin]-2-ium methanesulfonate; (3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione With potassium carbonate In toluene at 105℃; for 15h; Industrial scale;
Stage #2: With hydrogenchloride In isopropyl alcohol Industrial scale;
98.3%
Multi-step reaction with 2 steps
1.1: potassium carbonate; dibenzo-18-crown-6 / 5,5-dimethyl-1,3-cyclohexadiene / 3 h
2.1: methanol / 0.17 h / 60 - 65 °C
2.2: 1 h / 60 - 65 °C
View Scheme
C19H26N3S(1+)*CH3O3S(1-)

C19H26N3S(1+)*CH3O3S(1-)

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione
14805-29-9

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione

lurasidone

lurasidone

Conditions
ConditionsYield
With potassium carbonate In water for 10h; Reflux;95%
4-chlorobutyl bromide
6940-78-9

4-chlorobutyl bromide

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione
14805-29-9

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione

(3aR,4S,7R,7aS)-2-(4-chlorobutyl)hexahydro-1H-4,7-methanoisoindole-1,3(2H)-dione

(3aR,4S,7R,7aS)-2-(4-chlorobutyl)hexahydro-1H-4,7-methanoisoindole-1,3(2H)-dione

Conditions
ConditionsYield
With potassium carbonate In N,N-dimethyl-formamide at 0 - 20℃;95%
(3aR,7aR)-4’-(benzo[d]isothiazol-3-yl)octahydrospiro[isoindole-2,1’-piperazin]-2-ium methanesulfonate
186204-37-5

(3aR,7aR)-4’-(benzo[d]isothiazol-3-yl)octahydrospiro[isoindole-2,1’-piperazin]-2-ium methanesulfonate

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione
14805-29-9

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione

lurasidone

lurasidone

Conditions
ConditionsYield
With potassium carbonate In water; toluene for 8h; Product distribution / selectivity; Reflux;94.3%
With tetra(n-butyl)ammonium hydrogensulfate; potassium carbonate In water for 3h; Product distribution / selectivity; Reflux;94.3%
With potassium carbonate In N,N-dimethyl-formamide at 120℃; for 36h; Temperature;91.8%
(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione
14805-29-9

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione

propargyl bromide
106-96-7

propargyl bromide

N-Propargylbicyclo<2.2.1>heptane-2,3-di-exo-carboximide
105981-36-0

N-Propargylbicyclo<2.2.1>heptane-2,3-di-exo-carboximide

Conditions
ConditionsYield
With potassium carbonate In acetone for 1h; Heating;91%
1,4-dibromo-butane
110-52-1

1,4-dibromo-butane

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione
14805-29-9

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione

(1R,2S,3R,4S)-N-(4-bromobutyl)-2,3-bicyclo<2.2.1>heptanedicarboximide
99095-09-7

(1R,2S,3R,4S)-N-(4-bromobutyl)-2,3-bicyclo<2.2.1>heptanedicarboximide

Conditions
ConditionsYield
With potassium carbonate In acetone for 7h; Heating;90.2%
(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione
14805-29-9

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione

1-chloro-3,4-epoxybutane
13067-79-3

1-chloro-3,4-epoxybutane

(1R,2S,3R,4S)-N-(3,4-epoxybutyl)-2,3-bicyclo<2.2.1>heptanedicarboxamide
105981-37-1

(1R,2S,3R,4S)-N-(3,4-epoxybutyl)-2,3-bicyclo<2.2.1>heptanedicarboxamide

Conditions
ConditionsYield
With potassium carbonate In acetone for 2h; Heating;90.1%
Z-1,4-dichlorobutene
1476-11-5

Z-1,4-dichlorobutene

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione
14805-29-9

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione

N-(4-Chloro-2-cis-butenyl)bicyclo<2.2.1>heptane-2,3-di-exo-carboximide
106035-14-7

N-(4-Chloro-2-cis-butenyl)bicyclo<2.2.1>heptane-2,3-di-exo-carboximide

Conditions
ConditionsYield
With potassium carbonate In N,N-dimethyl-formamide at 90 - 100℃;90%
trans-1,4-dichlorobut-2-ene
110-57-6

trans-1,4-dichlorobut-2-ene

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione
14805-29-9

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione

N-(4-Chloro-2-trans-butenyl)bicyclo<2.2.1>heptane-2,3-di-exo-carboximide
105981-25-7

N-(4-Chloro-2-trans-butenyl)bicyclo<2.2.1>heptane-2,3-di-exo-carboximide

Conditions
ConditionsYield
With potassium carbonate In N,N-dimethyl-formamide at 90 - 100℃; for 2h;88.7%
(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione
14805-29-9

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione

8-(1,2-benzisothiazol-3-yl)-2-methyl-8-aza-5-azoniaspiro<4,5>decane methanesulfonate

8-(1,2-benzisothiazol-3-yl)-2-methyl-8-aza-5-azoniaspiro<4,5>decane methanesulfonate

A

(1R,2S,3R,4S)-N-<4-<4-(1,2-benzisothiazol-3-yl)-1-piperazinyl>-2-methylbutyl>-2,3-bicyclo<2.2.1>heptanedicarboximide

(1R,2S,3R,4S)-N-<4-<4-(1,2-benzisothiazol-3-yl)-1-piperazinyl>-2-methylbutyl>-2,3-bicyclo<2.2.1>heptanedicarboximide

B

(1R,2S,3R,4S)-N-<4-<4-(1,2-benzisothiazol-3-yl)-1-piperazinyl>-3-methylbutyl>-2,3-bicyclo<2.2.1>heptanedicarboximide

(1R,2S,3R,4S)-N-<4-<4-(1,2-benzisothiazol-3-yl)-1-piperazinyl>-3-methylbutyl>-2,3-bicyclo<2.2.1>heptanedicarboximide

Conditions
ConditionsYield
With dibenzo-18-crown-6; potassium carbonate In xylene for 10h; Heating;A 17.2%
B 82.7%
(3aR,7aR)-2,2-bis(2-hydroxyethyl)octahydro-1H-isoindolium mesylate
1421374-96-0

(3aR,7aR)-2,2-bis(2-hydroxyethyl)octahydro-1H-isoindolium mesylate

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione
14805-29-9

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione

(3aR,4S,7R,7aS)-2-(((1R,2R)-2-((bis(2-hydroxyethyl)amino)methyl)cyclohexyl)methyl)hexahydro-1H-4,7-methanoisoindole-1,3(2H)-dione

(3aR,4S,7R,7aS)-2-(((1R,2R)-2-((bis(2-hydroxyethyl)amino)methyl)cyclohexyl)methyl)hexahydro-1H-4,7-methanoisoindole-1,3(2H)-dione

Conditions
ConditionsYield
With potassium carbonate In N,N-dimethyl-formamide at 120℃; for 16h;80%
8-(2-quinolinyl)-8-aza-5-azoniaspiro<4.5>decane bromide
142415-01-8

8-(2-quinolinyl)-8-aza-5-azoniaspiro<4.5>decane bromide

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione
14805-29-9

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione

(1S,2R,6S,7R)-4-[4-(4-Quinolin-2-yl-piperazin-1-yl)-butyl]-4-aza-tricyclo[5.2.1.02,6]decane-3,5-dione

(1S,2R,6S,7R)-4-[4-(4-Quinolin-2-yl-piperazin-1-yl)-butyl]-4-aza-tricyclo[5.2.1.02,6]decane-3,5-dione

Conditions
ConditionsYield
With potassium carbonate; 18-crown-6 ether In xylene for 6h; Heating;76%
4-(3,4-Epoxybutyl)-1-(2-pyrimidinyl)piperazine
138274-13-2

4-(3,4-Epoxybutyl)-1-(2-pyrimidinyl)piperazine

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione
14805-29-9

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione

(1R*,2S*,3R*,4S*)-N-<2-Hydroxy-4-<4-(2-pyrimidinyl)-1-piperazinyl>butyl>-2,3-bicyclo<2.2.1>heptanedicarboximide
138273-99-1

(1R*,2S*,3R*,4S*)-N-<2-Hydroxy-4-<4-(2-pyrimidinyl)-1-piperazinyl>butyl>-2,3-bicyclo<2.2.1>heptanedicarboximide

Conditions
ConditionsYield
With potassium carbonate In butan-1-ol for 6h; Heating;59%
(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione
14805-29-9

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione

3-<4-(3,4-epoxybutyl)-1-piperazinyl>-1,2-benzisothiazole

3-<4-(3,4-epoxybutyl)-1-piperazinyl>-1,2-benzisothiazole

(1R,2S,3R,4S)-N-<4-<4-(1,2-benzisothiazol-3-yl)-1-piperazinyl>-2-hydroxybutyl>-2,3-bicyclo<2.2.1>heptanedicarboximide

(1R,2S,3R,4S)-N-<4-<4-(1,2-benzisothiazol-3-yl)-1-piperazinyl>-2-hydroxybutyl>-2,3-bicyclo<2.2.1>heptanedicarboximide

Conditions
ConditionsYield
With potassium carbonate In butan-1-ol for 9h; Heating;47.7%
C21H29N3O5S2

C21H29N3O5S2

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione
14805-29-9

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione

C29H36N4O4S

C29H36N4O4S

Conditions
ConditionsYield
With potassium carbonate In N,N-dimethyl-formamide at 133℃; for 2h; Molecular sieve;42%
1,4-dibromo-butane
110-52-1

1,4-dibromo-butane

N-(2-pyridinyl)piperazine
20980-22-7

N-(2-pyridinyl)piperazine

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione
14805-29-9

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione

tandospirone
87760-53-0

tandospirone

Conditions
ConditionsYield
With potassium carbonate; benzyltriethylammonium bromide 1.) toluene, reflux, 4 h, 2.) reflux, 5 h; Yield given. Multistep reaction;
8-(2-Pyrimidinyl)-8-aza-5-azoniaspiro[4.5]decane Bromide
81461-73-6

8-(2-Pyrimidinyl)-8-aza-5-azoniaspiro[4.5]decane Bromide

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione
14805-29-9

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione

tandospirone
87760-53-0

tandospirone

Conditions
ConditionsYield
With potassium carbonate; 18-crown-6 ether In xylene for 6h; Heating;
(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione
14805-29-9

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione

(1S,2R,6S,7R)-4-{4-[4-(3-Chloro-pyridin-2-yl)-piperazin-1-yl]-butyl}-4-aza-tricyclo[5.2.1.02,6]decane-3,5-dione
106708-43-4

(1S,2R,6S,7R)-4-{4-[4-(3-Chloro-pyridin-2-yl)-piperazin-1-yl]-butyl}-4-aza-tricyclo[5.2.1.02,6]decane-3,5-dione

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 90.2 percent / K2CO3 / acetone / 7 h / Heating
2: K2CO3, KI / acetonitrile / 8 h / Heating
View Scheme
Multi-step reaction with 2 steps
1: 90.2 percent / K2CO3 / acetone / 7 h / Heating
2: 34 percent / K2CO3, KI / dimethylformamide / 90 °C
View Scheme
(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione
14805-29-9

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione

(1R*,2S*,6R*,7S*)-5-hydroxy-4-<4-<4-(1,2-benzisothiazol-3-yl)-1-piperazinyl>butyl>-4-azatricyclo<5.2.1.02,6>decan-3-one

(1R*,2S*,6R*,7S*)-5-hydroxy-4-<4-<4-(1,2-benzisothiazol-3-yl)-1-piperazinyl>butyl>-4-azatricyclo<5.2.1.02,6>decan-3-one

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 90.2 percent / K2CO3 / acetone / 7 h / Heating
2: K2CO3, KI / acetonitrile / 8 h / Heating
3: 63 percent / NaBH4, 0.1percent aq. NaOH / propan-2-ol / 2 h / Heating
View Scheme
(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione
14805-29-9

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione

(1R,2S,3R,4S)-N-<4-<4-(1,2-benzisothiazol-3-yl)-1-piperazinyl>-3-hydroxybutyl>-2,3-bicyclo<2.2.1>heptanedicarboximide

(1R,2S,3R,4S)-N-<4-<4-(1,2-benzisothiazol-3-yl)-1-piperazinyl>-3-hydroxybutyl>-2,3-bicyclo<2.2.1>heptanedicarboximide

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 90.1 percent / K2CO3 / acetone / 2 h / Heating
2: 80.7 percent / butan-1-ol / 12 h / Heating
View Scheme
(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione
14805-29-9

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione

(1S,2R,6S,7R)-4-[4-(4-Oxo-1-phenyl-1,3,8-triaza-spiro[4.5]dec-8-yl)-butyl]-4-aza-tricyclo[5.2.1.02,6]decane-3,5-dione

(1S,2R,6S,7R)-4-[4-(4-Oxo-1-phenyl-1,3,8-triaza-spiro[4.5]dec-8-yl)-butyl]-4-aza-tricyclo[5.2.1.02,6]decane-3,5-dione

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 90.2 percent / K2CO3 / acetone / 7 h / Heating
2: K2CO3, KI / acetonitrile / 8 h / Heating
View Scheme
(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione
14805-29-9

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione

(1S,2R,6S,7R)-4-{4-[4-(4-Chloro-phenyl)-4-hydroxy-piperidin-1-yl]-butyl}-4-aza-tricyclo[5.2.1.02,6]decane-3,5-dione

(1S,2R,6S,7R)-4-{4-[4-(4-Chloro-phenyl)-4-hydroxy-piperidin-1-yl]-butyl}-4-aza-tricyclo[5.2.1.02,6]decane-3,5-dione

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 90.2 percent / K2CO3 / acetone / 7 h / Heating
2: 62.5 percent / K2CO3, KI / acetonitrile / 8 h / Heating
View Scheme
(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione
14805-29-9

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione

(1R,2S,3R,4S)-N-<4-<4-(1,2-benzisothiazol-3-yl)-1-piperazinyl>butyl>-2,3-bicyclo<2.2.1>heptanedicarboximide
106035-20-5

(1R,2S,3R,4S)-N-<4-<4-(1,2-benzisothiazol-3-yl)-1-piperazinyl>butyl>-2,3-bicyclo<2.2.1>heptanedicarboximide

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 90.2 percent / K2CO3 / acetone / 7 h / Heating
2: K2CO3, KI / acetonitrile / 8 h / Heating
View Scheme
(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione
14805-29-9

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione

(1S,2R,6S,7R)-4-{4-[4-(2-Oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidin-1-yl]-butyl}-4-aza-tricyclo[5.2.1.02,6]decane-3,5-dione

(1S,2R,6S,7R)-4-{4-[4-(2-Oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidin-1-yl]-butyl}-4-aza-tricyclo[5.2.1.02,6]decane-3,5-dione

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 90.2 percent / K2CO3 / acetone / 7 h / Heating
2: 66.4 percent / K2CO3, KI / acetonitrile / 8 h / Heating
View Scheme
(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione
14805-29-9

(3aR,4S,7R,7aS)‑4,7‑methylene‑1H‑isoindole‑1,3(2H)-dione

N-<4-(3-Methyl-1-piperazinyl)butyl>bicyclo<2.2.1>heptane-2,3-di-exo-carboximide
138274-11-0

N-<4-(3-Methyl-1-piperazinyl)butyl>bicyclo<2.2.1>heptane-2,3-di-exo-carboximide

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 90.2 percent / K2CO3 / acetone / 7 h / Heating
2: 100 percent / ethanol / Ambient temperature
View Scheme

14805-29-9Relevant articles and documents

PROCESS FOR THE INDUSTRIAL SYNTHESIS OF LURASIDONE

-

Page/Page column 13; 14, (2015/05/05)

Disclosed is a process for the industrial synthesis of Lurasidone from (1R,2R)-cyclohexane-1,2-diyldimethanol (1), 3-(piperazin-1- yl)benzo[d]isothiazole (3) and (3aR,4R,7R,7aS)-3a,4,7,7a-tetrahydro-4,7- methanoisobenzofuran-1,3-dione (6).). Said process is optimised to obtain Lurasidone with high yields and high purities by preparing highly pure synthesis intermediates, using critical raw materials and reagents in amounts close to the stoichiometric amounts, increasing productivity and reducing the costs and environmental impact of the process.

DEUTERATED 5-HT1A RECEPTOR AGONISTS

-

Paragraph 0388-0389, (2013/11/19)

The present invention relates to new deuterated derivatives of serotonin 5-HT1A receptor agonists of formula 1 and in particular to compositions and methods for therapeutic use.

INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF LURASIDONE AND SALTS THEREOF

-

, (2013/03/26)

The present invention relates to a process for the preparation of Lurasidone or a pharmaceutically acceptable salt thereof, a compound useful for the treatment of schizophrenia and bipolar disorder. The present invention further relates to processes for the preparation of Lurasidone intermediates, and to certain novel intermediates obtained by such processes.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 14805-29-9